About the Company
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XNCR News
Death in Cancer Drug Trial Hinders Xencor’s Shares
After reporting its fourth-quarter and full-year financials, Xencor Inc. sustained a steep drop in its share price.
Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)
Bassil Dahiyat, President & CEO of Xencor Inc (NASDAQ:XNCR), sold 12,528 shares of the company on March 5, 2024, according to ...
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the ...
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will ...
Xencor, Inc. (XNCR) Interactive Stock Chart - Yahoo Finance
PASADENA, Calif., February 20, 2024--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and ...
Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript
Good afternoon, and thank you for standing by. Welcome to Xencor's Fourth Quarter and Year End 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers ...
Xencor: Q4 Earnings Snapshot
PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Tuesday reported a loss of $19.1 million in its fourth quarter. The Pasadena, California-based company said it had a loss ...
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune ...
Loading the latest forecasts...